PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
No Data
No Data available this quarter, please select a different quarter.
2.48
Concerning net debt at 1.25-1.5x Biotechnology median of 1.69. Martin Whitman would look for hidden assets or restructuring potential.
-1238.62
Negative coverage while Biotechnology median is 0.00. Seth Klarman would scrutinize operating performance and look for turnaround catalysts.
1.17
Current ratio 50-75% of Biotechnology median of 2.07. Martin Whitman would look for hidden assets or working capital optimization.
No Data
No Data available this quarter, please select a different quarter.